The effect of cardiomyocytes derived from human dental-origin iPSCs on cardiac repair in murine model of acute myocardial infarction

doi:10.11958/20220106

Abstract

Abstract:

Objective To investigate the effect of myocardial cells differentiated from human SCAP-induced pluripotent stem cells (iPSCs) on the myocardial function of acute myocardial infarction (AMI) mice. Methods Human stem cells from apical papilla (SCAP) was reprogrammed to iPSCs with Sendai reprogramming kit and passed using single colony subcloning under feeder-free condition. Specific myocardial differentiation medium was utilized to induce iPSCs. Nine BALB/C male mice were divided into the normal group (no intervention), the AMI group (AMI modeling) and the experimental group (AMI modeling + iPSCs-CMs injection) using random number table method. AMI mice model was established by coronary artery ligation. The derived cardiomyocytes (CMs) were injected into peri-infarct region of mice, and myocardial function was accessed by echocardiography. Results The derived iPSCs exhibited morphology resembling with embryonic stem cells (ESCs) and formed three-germ layers in nude mice. The CMs were able to beat independently and expressed specific markers, α-actinin and TNNT-2. The success of AMI model was confirmed by immediate electrocardiogram after operation. Compared with the normal group, LVFS and LVEF decreased significantly in the AMI group, and LVFS and LVEF were significantly higher in the experimental group than those in the AMI group (P<0.05). Conclusion Local injection of human odontogenic iPSCs differentiated cardiomyocytes can significantly improve the cardiac function and promote myocardial repair in AMI mice.

Key words: myocardial infarction, induced pluripotent stem cells, myocytes, cardiac, mice, inbred BALB C, cardiac function, cardiac repair, stem cells from apical papilla

CLC Number:

R541.4
R781

Figures/Tables 4

References 17

[1]	ZALEWSKI J, NOWAK K, FURCZYNSKA P, et al. Complicating acute myocardial infarction. current status and unresolved targets for subsequent research[J]. J Clin Med, 2021, 10(24):5904. doi: 10.3390/jcm10245904.
[2]	CHOI D, HWANG K C, LEE K Y, et al. Ischemic heart diseases:current treatments and future[J]. J Control Release, 2009, 140(3):194-202. doi: 10.1016/j.jconrel.2009.06.016.
[3]	LEE J H, SEO S J. Biomedical application of dental tissue-derived induced pluripotent stem cells[J]. Stem Cells Int, 2016, 2016:9762465. doi: 10.1155/2016/9762465.
[4]	MAO A S, MOONEY D J. Regenerative medicine:Current therapies and future directions[J]. Proc Natl Acad Sci U S A, 2015, 112(47):14452-14459. doi: 10.1073/pnas.1508520112.
[5]	SANGANALMATH S K, BOLLI R. Cell therapy for heart failure:a comprehensive overview of experimental and clinical studies,current challenges,and future directions[J]. Circ Res, 2013, 113(6):810-834. doi: 10.1161/CIRCRESAHA.113.300219.
[6]	TAN X, DAI Q, GUO T, et al. Efficient generation of transgene- and feeder-free induced pluripotent stem cells from human dental mesenchymal stem cells and their chemically defined differentiation into cardiomyocytes[J]. Biochem Biophys Res Commun, 2018, 495(4):2490-2497. doi: 10.1016/j.bbrc.2017.12.007.
[7]	CHALISSERRY E P, NAM S Y, PARK S H, et al. Therapeutic potential of dental stem cells[J]. J Tissue Eng, 2017, 8:2041731417702531. doi: 10.1177/2041731417702531.
[8]	CAMBRIA E, PASQUALINI F S, WOLINT P, et al. Translational cardiac stem cell therapy:advancing from first-generation to next-generation cell types[J]. NPJ Regen Med, 2017, 2:17. doi: 10.1038/s41536-017-0024-1.
[9]	KANELIDIS A J, PREMER C, LOPEZ J, et al. Route of delivery modulates the efficacy of mesenchymal stem cell therapy for myocardial infarction:a meta-analysis of preclinical studies and clinical trials[J]. Circ Res, 2017, 120(7):1139-1150. doi: 10.1161/CIRCRESAHA.116.309819.
[10]	MENASCHÉ P, VANNEAUX V, HAGÈGE A, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment:First clinical case report[J]. Eur Heart J, 2015, 36(30):2011-2017. doi: 10.1093/eurheartj/ehv189.
[11]	FUNAKOSHI S, MIKI K, TAKAKI T, et al. Enhanced engraftment,proliferation,and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes[J]. Sci Rep, 2016, 6:19111. doi: 10.1038/srep19111.
[12]	JIANG X, YANG Z, DONG M. Cardiac repair in a murine model of myocardial infarction with human induced pluripotent stem cell-derived cardiomyocytes[J]. Stem Cell Res Ther, 2020, 11(1):297. doi: 10.1186/s13287-020-01811-7.
[13]	SHIBA Y, GOMIBUCHI T, SETO T, et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts[J]. Nature, 2016, 538(7625):388-391. doi: 10.1038/nature19815.
[14]	BUJA L M. Cardiac repair and the putative role of stem cells[J]. J Mol Cell Cardiol, 2019, 128:96-104. doi: 10.1016/j.yjmcc.2019. 01.022.
[15]	YE L, CHANG Y H, XIONG Q, et al. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells[J]. Cell Stem Cell, 2014, 15(6):750-761. doi: 10.1016/j.stem.2014.11.009.
[16]	LI H, YU B, YANG P, et al. Injectable AuNP-HA matrix with localized stiffness enhances the formation of gap junction in engrafted human induced pluripotent stem cell-derived cardiomyocytes and promotes cardiac repair[J]. Biomaterials, 2021, 279:121231. doi: 10.1016/j.biomaterials.2021.121231.
[17]	KOZANITI F K, METSIOU D N, MANARA A E, et al. Recent advancements in 3D printing and bioprinting methods for cardiovascular tissue engineering[J]. Bioengineering (Basel), 2021, 8(10):133. doi: 10.3390/bioengineering8100133.